Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference
mechanism to induce rapid, deep, and durable knockdown of target genes.
, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
The two types of small RNA molecules involved with RNA Interference
are microRNA (miRNA) and small interfering RNA (siRNA).The siRNA and miRNA can be administered in vivo after which it will be expressed as short hairpin RNA (shRNA) and ultimately become active siRNA.
Not only could this be faster than creating new GM crops, but the gene-silencing effects of RNA interference
last only a few days or weeks.
, short-interfering RNA, Glucose Regulated Protein 78, oncogene therapy
Most of the time, short interfering RNA (siRNA) - the type used for RNA interference
- is quickly broken down inside the body by enzymes that defend against infection by RNA viruses.
(RNAi) technology has been shown to be highly effective at reducing htt protein levels and reversing disease symptoms in mouse models.
The researchers, who are not associated with Benitec, used Benitec's DNA directed RNA interference
(ddRNAi) technology in their cervix cancer research.
; from biology to clinical applications.
One of the key means by which cells achieve this control is by "RNA interference
," a form of gene silencing where small pieces of RNA, called micro RNAs, obstruct the production of specific proteins by interacting with their genetic code.
Using a technique called RNA interference
to delete each of the 829 genes one at a time in the cancer cells, the team was able to explore how well paclitaxel worked in breast tumor cells if one gene was not working normally.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), Worcester, Mass., a a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference
(RNAi), has obtained commitments from several investors to purchase 2.7 million shares of its common stock at $6.00 per share and warrants to purchase 540,000 shares of its common stock for gross proceeds of $16.2 million.